Vimarsana
Biggest News Aggregation in the World

Page 9 - Poster Number News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Poster Number. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Poster Number Today - Breaking & Trending Today

DGAP-News: Immunic, Inc.: Immunic to Present Preclinical Data for Vidofludimus Calcium at the 17th Congress of ECCO and Announces Blinded Baseline Characteristics of Phase 2 Trial of Vidofludimus Calcium in Ulcerative Colitis - Vimarsana News

DGAP-News: Immunic, Inc.: Immunic to Present Preclinical Data for Vidofludimus Calcium at the 17th Congress of ECCO and Announces Blinded Baseline Characteristics of Phase 2 Trial of Vidofludimus Calcium in Ulcerative Colitis

DGAP-News: Immunic, Inc. / Key word(s): Conference/Study results Immunic to Present Preclinical Data for Vidofludimus Calcium at the 17th Congress of ECCO and Announces Blinded Baseline Characteristics

Hillstream BioPharma Provides Business Review with Key Pipeline Updates - Vimarsana News

Hillstream BioPharma Provides Business Review with Key Pipeline Updates

Press release content from Accesswire. The AP news staff was not involved in its creation.

Source: apnews.com
Cogent Biosciences to Present Preclinical Data on Bezuclastinib at AACR-NCI-EORTC Conference - Vimarsana News

Cogent Biosciences to Present Preclinical Data on Bezuclastinib at AACR-NCI-EORTC Conference

/PRNewswire/ -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases,...

Investegate |Galapagos NV Announcements | Galapagos NV: Galapagos to present data on rheumatoid arthritis at the upcoming European League Against Rheumatism (EULAR) congress - Vimarsana News

Investegate |Galapagos NV Announcements | Galapagos NV: Galapagos to present data on rheumatoid arthritis at the upcoming European League Against Rheumatism (EULAR) congress

ilgotinib Filgotinib is approved and marketed as Jyseleca (200mg and 100mg tablets) in the European Union, Great Britain, and Japan for the treatment of adults with moderate to severe active rheumatoid arthritis (RA) who have responded inadequately or are intolerant to one or more disease modifying anti-rheumatic drugs (DMARDs). Filgotinib may be used as monotherapy or in combination with methotrexate (MTX). The European Summary of Product Characteristics for filgotinib, which includes contraindications and special warnings and precautions, is available at www.ema.europa.eu. The interview fo...

Galapagos NV: Galapagos to present data on rheumatoid arthritis at the upcoming European League Against Rheumatism (EULAR) congress - Vimarsana News

Galapagos NV: Galapagos to present data on rheumatoid arthritis at the upcoming European League Against Rheumatism (EULAR) congress

Mechelen, Belgium, 27 May 2021, 22:01 CET, - Galapagos NV (Euronext & Nasdaq: GLPG) today announced that 15 abstracts, including scientific updates, and data providing further understanding on the